GLAUKOS Corp (GKOS) senior executive stock sale disclosed. The company’s Senior Vice President and Chief Financial Officer reported selling 315 shares of common stock on 11/25/2025 at a price of $105 per share. After this transaction, the executive beneficially owns 50,488 shares of GLAUKOS common stock.
The filing notes that these sales were carried out under a Rule 10b5-1 trading plan adopted on June 11, 2025, which is a pre-arranged plan designed to allow insiders to sell stock over time according to set instructions. The reported holdings include 13,751 restricted stock units that have not yet vested or been delivered and 167 stock units acquired through the company’s employee stock purchase plan.
A shareholder of GKOS filed a Form 144 indicating an intent to sell 315 shares of common stock through Fidelity Brokerage Services LLC on the NYSE. The shares have an aggregate market value of 33,075.00 based on the information provided, with the sale targeted for 11/25/2025. These 315 shares came from restricted stock that vested on 04/01/2025 and were received as compensation from the issuer on that date. The filing notes that there were 57,434,740 shares outstanding of the same class of common stock, providing context for the size of this planned sale.
Glaukos Corp (GKOS) reported an insider stock sale by its President & COO. On 11/18/2025, the executive sold 19,340 shares of Glaukos common stock at a price of $90 per share. After this transaction, the reporting person beneficially owns 92,366 shares, which includes 62,605 restricted stock units that have not yet vested or been delivered. The filing notes that the report is made by a single reporting person and is signed by an attorney-in-fact on the insider’s behalf.
Glaukos Corporation (GKOS) reported that an affiliated holder plans to sell 19,340 common shares under Rule 144. The shares will be sold through Fidelity Brokerage Services LLC on or about 11/18/2025 on the NYSE, with an indicated aggregate market value of $1,740,600. The filing notes that 57,434,740 common shares were outstanding. Most of the shares being sold were acquired between March 2023 and April 2024 through restricted stock vesting as compensation, along with a smaller amount purchased through the company’s employee stock purchase plan. The signer represents that they are not aware of undisclosed material adverse information about Glaukos.
Glaukos Corporation announced it intends to use an updated investor presentation, furnished as Exhibit 99.1, in meetings with investors and other stakeholders. The materials are provided under Item 7.01 (Regulation FD) and are available on the company’s investor website at investors.glaukos.com.
The company states the information in Item 7.01 and Exhibit 99.1 is not deemed filed under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly referenced. The exhibit is dated November 2025.
Glaukos Corporation reported Q3 2025 results. Net sales were $133.5 million for the three months ended September 30, 2025, up from $96.7 million a year ago, while net loss narrowed to $16.2 million with basic and diluted net loss per share of $0.28.
Glaucoma products contributed $110.2 million and Corneal Health $23.3 million in the quarter. Gross profit was $104.7 million; operating expenses were $121.1 million, leading to a loss from operations of $16.4 million. Cash and cash equivalents were $98.2 million and short‑term investments $175.5 million at quarter‑end. Total assets were $999.4 million and stockholders’ equity was $769.5 million.
Year to date, net sales reached $364.3 million versus $278.0 million last year, with net loss of $54.0 million. The company closed the Mobius Therapeutics acquisition with $24.5 million consideration and purchased an adjacent Aliso Viejo building for $16.6 million. Accounts receivable rose, driven by iDose TR’s extended payment terms. Shares outstanding were 57,434,740 as of October 29, 2025.
Glaukos Corporation filed a current report describing how it shared its latest quarterly information with investors. On October 29, 2025, the company issued a press release announcing its financial results for the third quarter ended September 30, 2025, which is furnished as Exhibit 99.1. Glaukos also prepared a Quarterly Summary with supplemental business and financial information for the same period, furnished as Exhibit 99.2 and made available in the Financials & Filings section of its investor relations website. The company notes that these materials are furnished, not filed, under securities laws unless later specifically incorporated by reference.
Joseph E. Gilliam, President & COO of Glaukos Corporation (GKOS), reported a transaction on 09/23/2025 where 1,056 shares of common stock were disposed of at $84.69 per share. The filing states these shares were withheld by the issuer to satisfy tax withholding obligations when restricted stock units vested and were delivered (these RSUs were originally granted on March 18, 2021). After the withholding, the reporting person beneficially owns 111,706 shares, of which 62,605 restricted stock units remain unvested and undelivered. The Form 4 is signed by an attorney-in-fact on 09/24/2025.
Glaukos insider sale disclosed: Tomas Navratil, Chief Development Officer, reported multiple dispositions of Glaukos common stock on September 22-23, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted June 12, 2025. Transaction prices ranged from $82.20 to $85.11 (weighted averages reported per block). After the reported transactions, the reporting person beneficially owned 75,907 shares, which include unvested restricted stock units (the filing notes 42,535 RSUs still unvested). Some shares were withheld to satisfy tax withholding upon RSU vesting.
Thomas W. Burns, who serves as Chairman & CEO and a director of Glaukos Corporation (GKOS), reported a disposition of 4,059 shares of common stock on 09/23/2025 at a price of $84.69 per share due to shares withheld for tax obligations upon vesting of previously granted restricted stock units. After the reported transaction, he beneficially owns 150,705 shares directly and holds additional indirect holdings through family and trust vehicles totaling 1,452,039 shares when summing disclosed indirect positions and unvested units: 893,932 (Burns Family Trust), 238,107 (Burns Annuity Trust), 120,000 (Burns Charitable Remainder Trust), 100,000 (Thomas W. Burns Irrevocable Trust), and 100,000 (Janet M. Burns Irrevocable Trust). The filing also notes 87,537 restricted stock units that have not yet vested or been delivered.